Classes
DEA Class; Rx
Common Brand Names; Ryzodeg
- Antidiabetics, Insulin Combos
Description
Insulin degludec: Long-acting basal insulin
Insulin aspart: Rapid-acting insulin
Insulin and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue
Indications
Indicated to improve glycemic control in adults with diabetes mellitus
Contraindications
During episodes of hypoglycemia
Documented hypersensitivity
Adverse Effects
Nasopharyngitis (11.1-24.6%)
Severe hypoglycemia (0.4-13.3%)
Headache (5.6-9.7%)
URT infection (5.7-9.1%)
Influenza (6.9%)
Peripheral edema (1.8-2.2%)
Injection site reaction (2%)
Allergic reaction
Lipodystrophy
Localized cutaneous amyloidosis at injection site
Hypersensitivity
Hypokalemia
Warnings
Do not share, even if the needle is changed; sharing poses a risk for transmission of blood-borne pathogens
Changes in insulin, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia; these changes should be made cautiously and only under medical supervision, and the frequency of blood glucose monitoring should be increased
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur
All insulin products cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia; monitor potassium levels in patients at risk for hypokalemia including patients using potassium-lowering medications or those taking medications sensitive to serum potassium concentrations; treat if indicated
Thiazolidinediones, which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists can cause dose-related fluid retention, particularly when used in combination with insulin; this may lead to or exacerbate heart failure
Pregnancy and Lactation
There are no available data in pregnant women to inform a drug-associated risk for major birth defects and miscarriage
There are no available data in pregnant women to inform a drug-associated risk for major birth defects and miscarriage
Maximum Dosage
Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.
How supplied
Insulin degludec/insulin aspart
prefilled pen
- insulin degludec 70 units/insulin aspart 30 units per mL (ie, 100 units/mL for combination)